Advanced basal cell carcinoma, the hedgehog pathway, and treatment options – role of smoothened inhibitors

od Fecher, Leslie A, Sharfman, William H
Izdano u Biologics (2015)

Ipilimumab and Its Toxicities: A Multidisciplinary Approach

od Fecher, Leslie A., Agarwala, Sanjiv S., Hodi, F. Stephen, Weber, Jeffrey S.
Izdano 2013

Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy

od Rizzo, Jason M., Fecher, Leslie A., Chan, May P., Durham, Alison B.
Izdano u JAAD Case Rep (2018)

Metastatic Merkel cell carcinoma response to nivolumab

od Walocko, Frances M., Scheier, Benjamin Y., Harms, Paul W., Fecher, Leslie A., Lao, Christopher D.
Izdano u J Immunother Cancer (2016)

Erratum to: Metastatic Merkel cell carcinoma response to nivolumab

od Walocko, Frances M., Scheier, Benjamin Y., Harms, Paul W., Fecher, Leslie A., Lao, Christopher D.
Izdano u J Immunother Cancer (2017)

An adolescent with uveal melanoma and BAP1 tumor predisposition syndrome

od Young, Kelly Z., Fossum, Sara L., Lowe, Lori, Else, Tobias, Fecher, Leslie A., Demirci, Hakan, Cha, Kelly B.
Izdano u JAAD Case Rep (2020)

Acute visual loss after ipilimumab treatment for metastatic melanoma

od Wilson, Melissa A., Guld, Kelly, Galetta, Steven, Walsh, Ryan D., Kharlip, Julia, Tamhankar, Madhura, McGettigan, Suzanne, Schuchter, Lynn M., Fecher, Leslie A.
Izdano u J Immunother Cancer (2016)

Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study

od Chu, Emily Y., Wanat, Karolyn A., Miller, Christopher J., Amaravadi, Ravi K., Fecher, Leslie A., Brose, Marcia S., McGettigan, Suzanne, Giles, Lydia R., Schuchter, Lynn M., Seykora, John T., Rosenbach, Misha
Izdano u J Am Acad Dermatol (2012)

Collapse of the CD27+ B cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers

od Carpenter, Erica L., Mick, Rosemarie, Rech, Andrew J., Beatty, Gregory L., Colligon, Theresa A., Rosenfeld, Myrna R., Kaplan, David E., Chang, Kyong-Mi, Domchek, Susan M., Kanetsky, Peter A., Fecher, Leslie A., Flaherty, Keith T., Schuchter, Lynn M., Vonderheide, Robert H.
Izdano 2009

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

od Lin, Heng, Wei, Shuang, Hurt, Elaine M., Green, Michael D., Zhao, Lili, Vatan, Linda, Szeliga, Wojciech, Herbst, Ronald, Harms, Paul W., Fecher, Leslie A., Vats, Pankaj, Chinnaiyan, Arul M., Lao, Christopher D., Lawrence, Theodore S., Wicha, Max, Hamanishi, Junzo, Mandai, Masaki, Kryczek, Ilona, Zou, Weiping
Izdano u J Clin Invest (2018)

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

od Lin, Heng, Wei, Shuang, Hurt, Elaine M., Green, Michael D., Zhao, Lili, Vatan, Linda, Szeliga, Wojciech, Herbst, Ronald, Harms, Paul W., Fecher, Leslie A., Vats, Pankaj, Chinnaiyan, Arul M., Lao, Christopher D., Lawrence, Theodore S., Wicha, Max, Hamanishi, Junzo, Mandai, Masaki, Kryczek, Ilona, Zou, Weiping
Izdano u J Clin Invest (2018)

Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

od Kim, Kevin B., Kefford, Richard, Pavlick, Anna C., Infante, Jeffrey R., Ribas, Antoni, Sosman, Jeffrey A., Fecher, Leslie A., Millward, Michael, McArthur, Grant A., Hwu, Patrick, Gonzalez, Rene, Ott, Patrick A., Long, Georgina V., Gardner, Olivia S., Ouellet, Daniele, Xu, Yanmei, DeMarini, Douglas J., Le, Ngocdiep T., Patel, Kiran, Lewis, Karl D.
Izdano u J Clin Oncol (2013)

Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma

od Rangwala, Reshma, Leone, Robert, Chang, Yunyoung C, Fecher, Leslie A, Schuchter, Lynn M, Kramer, Amy, Tan, Kay-See, Heitjan, Daniel F, Rodgers, Glenda, Gallagher, Maryann, Piao, Shengfu, Troxel, Andrea B, Evans, Tracey L, DeMichele, Angela M, Nathanson, Katherine L, O’Dwyer, Peter J, Kaiser, Jonathon, Pontiggia, Laura, Davis, Lisa E, Amaravadi, Ravi K
Izdano 2014

Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma

od Rangwala, Reshma, Chang, Yunyoung C, Hu, Janice, Algazy, Kenneth M, Evans, Tracey L, Fecher, Leslie A, Schuchter, Lynn M, Torigian, Drew A, Panosian, Jeffrey T, Troxel, Andrea B, Tan, Kay-See, Heitjan, Daniel F, DeMichele, Angela M, Vaughn, David J, Redlinger, Maryann, Alavi, Abass, Kaiser, Jonathon, Pontiggia, Laura, Davis, Lisa E, O’Dwyer, Peter J, Amaravadi, Ravi K
Izdano 2014

Activity of the MEK Inhibitor Trametinib (GSK1120212) in Advanced Melanoma in a Phase I, Dose-escalation Trial

od Falchook, Gerald S, Lewis, Karl D, Infante, Jeffrey R, Gordon, Michael S, Vogelzang, Nicholas J, DeMarini, Douglas J, Sun, Peng, Moy, Christopher, Szabo, Stephen A., Roadcap, Lori T, Peddareddigari, Vijay G R, Lebowitz, Peter F, Le, Ngocdiep T, Burris, Howard A, Messersmith, Wells A, O'Dwyer, Peter J, Kim, Kevin B., Flaherty, Keith, Bendell, Johanna C., Gonzalez, Rene, Kurzrock, Razelle, Fecher, Leslie A
Izdano 2012

Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

od Rivera, Donna R., Peters, Solange, Panagiotou, Orestis A., Shah, Dimpy P., Kuderer, Nicole M., Hsu, Chih-Yuan, Rubinstein, Samuel M., Lee, Brendan J., Choueiri, Toni K., de Lima Lopes, Gilberto, Grivas, Petros, Painter, Corrie A., Rini, Brian I., Thompson, Michael A., Arcobello, Jonathan, Bakouny, Ziad, Doroshow, Deborah B., Egan, Pamela C., Farmakiotis, Dimitrios, Fecher, Leslie A., Friese, Christopher R., Galsky, Matthew D., Goel, Sanjay, Gupta, Shilpa, Halfdanarson, Thorvardur R., Halmos, Balazs, Hawley, Jessica E., Khaki, Ali Raza, Lemmon, Christopher A., Mishra, Sanjay, Olszewski, Adam J., Pennell, Nathan A., Puc, Matthew M., Revankar, Sanjay G., Schapira, Lidia, Schmidt, Andrew, Schwartz, Gary K., Shah, Sumit A., Wu, Julie T., Xie, Zhuoer, Yeh, Albert C., Zhu, Huili, Shyr, Yu, Lyman, Gary H., Warner, Jeremy L.
Izdano u Cancer Discov (2020)

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

od Bettegowda, Chetan, Sausen, Mark, Leary, Rebecca J., Kinde, Isaac, Wang, Yuxuan, Agrawal, Nishant, Bartlett, Bjarne R., Wang, Hao, Luber, Brandon, Alani, Rhoda M., Antonarakis, Emmanuel S., Azad, Nilofer S., Bardelli, Alberto, Brem, Henry, Cameron, John L., Lee, Clarence C., Fecher, Leslie A., Gallia, Gary L., Gibbs, Peter, Le, Dung, Giuntoli, Robert L., Goggins, Michael, Hogarty, Michael D., Holdhoff, Matthias, Hong, Seung-Mo, Jiao, Yuchen, Juhl, Hartmut H., Kim, Jenny J., Siravegna, Giulia, Laheru, Daniel A., Lauricella, Calogero, Lim, Michael, Lipson, Evan J., Marie, Suely Kazue Nagahashi, Netto, George J., Oliner, Kelly S., Olivi, Alessandro, Olsson, Louise, Riggins, Gregory J., Sartore-Bianchi, Andrea, Schmidt, Kerstin, Shih, le-Ming, Oba-Shinjo, Sueli Mieko, Siena, Salvatore, Theodorescu, Dan, Tie, Jeanne, Harkins, Timothy T., Veronese, Silvio, Wang, Tian-Li, Weingart, Jon D., Wolfgang, Christopher L., Wood, Laura D., Xing, Dongmei, Hruban, Ralph H., Wu, Jian, Allen, Peter J., Schmidt, C. Max, Choti, Michael A., Velculescu, Victor E., Kinzler, Kenneth W., Vogelstein, Bert, Papadopoulos, Nickolas, Diaz, Luis A.
Izdano 2014